360 related articles for article (PubMed ID: 22177244)
21. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer in the elderly: a histological assessment.
Tse GM; Tan PH; Lau KM; de Andrade VP; Lui PC; Vong JS; Chaiwun B; Lam CC; Yu AM; Moriya T
Histopathology; 2009 Oct; 55(4):441-51. PubMed ID: 19817895
[TBL] [Abstract][Full Text] [Related]
23. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
24. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
25. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
26. [Primary neuroendocrine tumors of the breast: a retrospective study of 21 cases and literature review].
Feki J; Fourati N; Mnif H; Khabir A; Toumi N; Khanfir A; Boudawara T; Amouri H; Daoud J; Frikha M
Cancer Radiother; 2015 Aug; 19(5):308-12. PubMed ID: 26215367
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine carcinomas of the uterine cervix: A clinicopathological study.
Sitthinamsuwan P; Angkathunyakul N; Chuangsuwanich T; Inthasorn P
J Med Assoc Thai; 2013 Jan; 96(1):83-90. PubMed ID: 23720983
[TBL] [Abstract][Full Text] [Related]
29. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior.
Pettinato G; Manivel CJ; Panico L; Sparano L; Petrella G
Am J Clin Pathol; 2004 Jun; 121(6):857-66. PubMed ID: 15198358
[TBL] [Abstract][Full Text] [Related]
30. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
31. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
32. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
34. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
35. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems.
Righi L; Sapino A; Marchiò C; Papotti M; Bussolati G
Semin Diagn Pathol; 2010 Feb; 27(1):69-76. PubMed ID: 20306832
[TBL] [Abstract][Full Text] [Related]
37. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.
Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS
J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436
[TBL] [Abstract][Full Text] [Related]
38. Molecular subtyping of male breast cancer by immunohistochemistry.
Kornegoor R; Verschuur-Maes AH; Buerger H; Hogenes MC; de Bruin PC; Oudejans JJ; van der Groep P; Hinrichs B; van Diest PJ
Mod Pathol; 2012 Mar; 25(3):398-404. PubMed ID: 22056953
[TBL] [Abstract][Full Text] [Related]
39. E-cadherin expression in molecular types of breast carcinoma.
Ionescu Popescu C; Giuşcă SE; Liliac L; Avadanei R; Ceauşu R; Cîmpean AM; Balan R; Amălinei C; Ciobanu Apostol D; Căruntu ID
Rom J Morphol Embryol; 2013; 54(2):267-73. PubMed ID: 23771069
[TBL] [Abstract][Full Text] [Related]
40. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
